ReviewMetabolomics : Official journal of the Metabolomic Society2025
Progress and perspectives of metabolic biomarkers in blood sample for diabetic microvascular complications.
Review in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolomics approaches for the early detection and therapeutics: type 2 diabetes-induced diabetic kidney disease-a systematic review and meta-analysis.Metabolomics : Official journal of the Metabolomic Society · 2025Pooled it
- Methodological improvements are needed in network meta analyses of antidiabetic drugs for type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDiabetes mellitus refers to a group of metabolic diseases characterized by chronic hyperglycemia due to multiple etiological factors. As the disease progresses, patients gradually develop microvascular complications, including diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy. However, current clinical methods for detecting these microvascular complications are limitations, thus primary prevention and early diagnosis are of great importance. AIM OF REVIEW: This review summarizes the known blood biomarkers of diabetic microvascular complications, classified according to type of structure, including amino acid metabolism, lipid metabolism, carnitine metabolism, organic acid metabolism, etc., which can be used for the simultaneous typing of diabetes mellitus based on microvascular complications, and to search for the trend of changes to lay the foundation for early diagnosis and understanding of the pathogenesis of diabetic microvascular complications, including oxidative stress, and mitochondrial dysfunction. Searches for the trend of changes to lay the foundation for early diagnosis and understanding of the pathogenesis of diabetic microvascular complications, including oxidative stress, mitochondrial dysfunction. KEY SCIENTIFIC CONCEPTS OF REVIEW: Due to the limitations of diagnostic criteria for diabetic microvascular complications, some patients already have the disease for which they are being tested. Metabolomics reflects the physiological state of an organism by analyzing the small molecules metabolites present in a biological tissue that are related to clinical phenotypes, providing a snapshot of the physiological and pathophysiological metabolic processes occurring within that organism at any given time, thus opening the door for the development of diagnostic biomarkers and precise treatment. In clinical metabolomics, blood is considered a specialized type of connective tissue, which allows it to transport substances throughout the body, connecting different systems together. Also, blood components are probably the most frequently used matrix in metabolomics studies. Therefore, metabolomics is used to analyze blood biomarkers that reflect the course of diabetes and explore the pathways involved in the pathophysiology of the three most common diabetic microvascular complications. Finally, in this review, we discuss the current limitations of metabolomic analysis, and the integrative multi-omics data, including genomics, transcriptomics, and proteomics, required for developing specific biomarkers for diabetic microvascular complications.
Indexed as
Identifiers
40164927What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.